Source: Guideline 2015
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raghu, G., Rochwerg, B., Zhang, Y., et al.. Treatment of Idiopathic Pulmonary Fibrosis. Guideline 2015

Member's Comments

No comment yet.

Related content which might interest you: Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Impact of depression on patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Characterize Idiopathic Pulmonary Fibrosis using Respiratory Oscillometry Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Epidemiology of Idiopathic Pulmonary Fibrosis in Australia Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Methylprednisolone pulse therapy in Acute Exacerbations of Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Implication of FGFR4 and its ligands in Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Diagnosis and Treatment of Chronic Pulmonary Embolism Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease Year: 2014